Oral ondansetron reduces the proportion of children that continue to vomit within the first 4 hours after presentation at the OHS when added to oral rehydration therapy compared to oral rehydration therapy alone.
ID
Bron
Verkorte titel
Aandoening
Huisartsgeneeskunde (General Practice), Kinderen (Children), Gastro-enteritis (gastroenteritis), Kosteneffectiviteit (cost-effectiveness), Misselijkheid (vomiting)
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The proportion of children that continue to vomit within the first 4 hours after presentation at the OHS with acute gastro-enteritis.
Achtergrond van het onderzoek
OBJECTIVE: To evaluate cost-effectiveness of ondansetron in children with acute gastro-enteritis (AGE ) and vomiting at a general practitioner cooperative out-of-hours service (OHS)
RESEARCH QUESTION: What is the cost-effectiveness of ondansetron and oral rehydration therapy (ORT) compared to ORT alone?
HYPOTHESIS: With an effective one-intake-treatment that stops vomiting and consequently facilitates ORT, persisting vomiting and referral rate will be reduced and consequently will reduce costs
STUDY DESIGN: Pragmatic Randomized Controlled Trial
STUDY POPULATION: Vomiting children aged 6 months to 6 years with AGE attending OHS
INTERVENTION: Oral ondansetron added to ORT
SAMPLE SIZE We have to include 220 children in order to observe a significant reduction in persisting vomiting from an expected 35% to 15%
Doel van het onderzoek
Oral ondansetron reduces the proportion of children that continue to vomit within the first 4 hours after presentation at the OHS when added to oral rehydration therapy compared to oral rehydration therapy alone.
Onderzoeksopzet
Baseline (=T0), every hour after baseline for the first four hours (=T1 - T4) for the first day. Second day until the seventh (=T5-T11)
Onderzoeksproduct en/of interventie
Weight-based dose of oral ondansetron added to oral rehydration therapy.
Publiek
M.Y. Berger
Postbus 196
Groningen 9700 AD
The Netherlands
Email: m.y.berger@umcg.nl
Wetenschappelijk
M.Y. Berger
Postbus 196
Groningen 9700 AD
The Netherlands
Email: m.y.berger@umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Aged 6 months to 6 years;
2. At least four reported episodes of vomiting or diarrhoea during the last twenty-four hours preceding presentation
3. At least one reported episode of vomiting within the four hours preceding presentation;
4. Diagnosed with AGE by a general practitioner at the OHS.
5. Parental written informed consent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Use of anti-emetics in the previous 6 hours;
2. Known renal failure or hypoalbuminemia (as this could affect the assessment of hydration status);
3. Known diabetes mellitus or inflammatory bowel disease (as this could increase the risk of a complicated course);
4. A history of abdominal surgery, with suspected recurrence of original abdominal symptoms or strangulation ileus explaining current symptoms, according to the general practitioner.
5. Known sensitivity to 5-HT3 receptor antagonists;
6. Known prolonged QT interval;
7. Current use of QT prolonging medication;
8. Previous enrolment in the study.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5830 |
| NTR-old | NTR5986 |
| CCMO | NL59128.042.16 |
| OMON | NL-OMON43048 |